Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alzamend Neuro, Inc

0.6900
+0.01061.56%
Post-market: 0.69000.00000.00%16:40 EDT
Volume:93.34K
Turnover:64.34K
Market Cap:4.55M
PE:-0.43
High:0.7075
Open:0.6800
Low:0.6800
Close:0.6794
Loading ...

EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels

Benzinga
·
19 Feb

Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?

Zacks
·
23 Jan

Alzamend Neuro to Present at the Sequire Investor Summit

Business Wire
·
15 Jan

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

Business Wire
·
18 Dec 2024

Alzamend Neuro Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
16 Dec 2024

Alzamend Neuro says net cash gained by financing activity $8.3M

TIPRANKS
·
12 Dec 2024

Alzamend Neuro Q2 EPS $(0.40) Beats $(0.77) Estimate

Benzinga
·
12 Dec 2024

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

THOMSON REUTERS
·
12 Dec 2024

Press Release: Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

Dow Jones
·
12 Dec 2024

Alzamend Neuro announces full data set from nonclinical AL001 study

TIPRANKS
·
19 Nov 2024

BRIEF-Alzamend Neuro Announces Full Data Set From Its Nonclinical Study

Reuters
·
19 Nov 2024

Alzamend Neuro Inc: Both Treatments Had No Negative Impact on Mice's Body Weight or Clinical Signs During Treatment Period

THOMSON REUTERS
·
19 Nov 2024

Alzamend Neuro Announces Full Data Set From Its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures Between Al001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

THOMSON REUTERS
·
19 Nov 2024

Alzamend Neuro Inc: at a Low Dose, Al001 Evidenced Consistently Higher Lithium Concentrations Than Lithium Carbonate Within Critical Brain Regions

THOMSON REUTERS
·
19 Nov 2024

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

Business Wire
·
19 Nov 2024

EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential

Benzinga
·
19 Nov 2024

Alzamend Neuro Inc : Ascendiant Capital Markets Cuts Target Price to $35 From $50

THOMSON REUTERS
·
11 Nov 2024

Alzamend Neuro Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
11 Nov 2024